Autolus is a clinical-stage, biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer. Utilising its advanced cell programming and manufacturing technologies, Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours.
Jan 14, 2019Autolus Therapeutics Enters Lease with Alexandria Real Estate Equities, Inc. for Future Commercial-Scale Manufacturing Site and U.S. Headquarters
Dec 20, 2018Autolus Therapeutics to Join NASDAQ Biotechnology Index
Dec 02, 2018Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting
More events are coming soon.